5 Must-Read Quotes for Robotic Surgery Investors

Something big just happened in the robotic surgical industry. Last week, a small company called TransEnterix (NYSEMKT: TRXC) won FDA approval for its Senhance Robotic Surgical System. The regulatory win marks the end of an era for Intuitive Surgical (NASDAQ: ISRG), a company whose da Vinci system has enjoyed monopoly status in the U.S. since its launch at the turn of the century.

Does this approval spell trouble for Intuitive Surgical, or is TransEnterix simply too small (and too late) for it to matter?

To answer these questions, I got in touch with TransEnterix's CEO Todd Pope. Below are some highlights from our conversation (which have been lightly edited for clarity).

Source: Fool.com